Marijuana Inc (ID) (MAJI)

$MAJI NEWS: NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth

NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth

Exousia Pro, Inc.
Wed, June 17, 2026 at 7:00 AM EDT 4 min read

BOCA RATON, Fla., June 17, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI) today announced a strategic pivot, evolutionary restructuring, and operational alignment designed to transition the company from a traditional development-stage biotech entity into a fully integrated, high-revenue healthcare platform. By seamlessly uniting its pioneering scientific innovations, recurring-revenue telehealth segments, and a massive, pre-existing patient distribution outlet, NexTel is positioning itself to rapidly commercialize next-generation medical solutions and maximize shareholder value.


At the center of this unified ecosystem are the company's three primary operational drivers: Chairman of the Advisory Board Dr. Marvin Hausman, MD; world-renowned neuroscientist and inventor Dr. Kimi Sugaya; and healthcare entrepreneur Casey Barksdale. Together, this leadership trio bridges the critical gap that historically stalls biotech companies by connecting brilliant scientific discovery directly to an established, high-volume commercial pipeline.

The Innovation Meets Distribution Ecosystem

While many medical technology companies spend years raising dilutive capital while waiting for a breakthrough product, NexTel is executing a dual-track strategy. The company has integrated its recent acquisitions, JumpstartRx and NueVistraMed, to establish an immediate, non-dilutive, foundational revenue stream that is currently generating $135,000 to $140,000 per month.

Crucially, these segments form a turnkey healthcare infrastructure. Through the extensive industry relationships and networks built by Casey Barksdale, NexTel has secured a massive, proprietary distribution channel that eliminates traditional barriers to market entry. This single sales channel boasts an extraordinary commercial footprint:


Active Patient Reach: Interacted with over 300,000 active patients just last month alone.

Rapid Expansion: Currently onboarding 5,000 new patients per day.

Facility Network: Encompasses more than 1,500 online clinics and over 350 physical medical facilities.


This unprecedented distribution outlet provides Dr. Hausman and Dr. Sugaya with an immediate, built-in audience for all viable medical products and diagnostic tools developed by the company.

Driving the Home Runs: Advanced Diagnostic Pipeline

This powerful sales funnel is perfectly timed to support the commercial launch of NexTel's flagship medical technology: the Nanog Cancer Screening Test. Invented by Dr. Sugaya and backed by a fully granted, protected underlying patent (US 11,193,174 issued on December 7, 2021), the Nanog platform utilizes saliva samples rather than invasive blood draws to isolate and analyze exosomes—tiny cellular particles—to detect cancer-related signals at an ultra-early stage, long before traditional methods can identify a tumor's physical presence.


Dr. Hausman's extensive decades of experience as a surgeon, clinical researcher, and successful corporate entrepreneur (having previously founded Medco Research, which ultimately became part of Pfizer) is driving the clinical and regulatory pathway for the Nanog platform. Institutional Review Board (IRB) clinical testing is slated to begin shortly to validate earlier results, with management targeting an aggressive commercial launch timeline as early as September or October 2026.

The Revenue Engine: From Singles to Home Runs

By combining steady operational "singles and doubles" with high-impact scientific "home runs," NexTel is breaking the mold of standard biotechnology. Every component of the company is designed to feed into the next. In addition to its current telehealth and diagnostic initiatives, NexTel is advancing a high-volume prescription-fulfillment program. Once fully operational, this program is projected to process approximately 2,000 prescriptions per day at an estimated $4 per prescription, layering an additional, highly predictable revenue stream onto the platform.


"What we are building at NexTel is a complete healthcare ecosystem," said Matt Dwyer, CEO of NexTel Medical. "We aren't asking our shareholders to wait years for a single moonshot technology to clear regulatory hurdles before seeing commercial traction. We have operational segments generating revenue today, a revolutionary diagnostic technology entering clinical validation, and a massive distribution channel adding 5,000 patients a day to receive these products. Dr. Hausman, Dr. Sugaya, and Casey Barksdale have brought the pieces together to make NexTel a formidable force in modern healthcare."

About NexTel Medical Corp.

NexTel Medical Corp. (OTC Pink: MAJI) is a pioneering biotechnology leader and diversified healthcare platform at the forefront of exosome research, clinical diagnostics, and wellness accessibility. The Company specializes in developing proprietary, next-generation, exosome-based delivery systems and non-invasive screening tools—including its flagship Maxasome™ line—utilizing proprietary filtration and stabilization techniques to deliver high-purity solutions for personalized medicine. By combining these disruptive medical technologies with immediate, recurring-revenue operations from its strategic acquisitions of JumpstartRx and NueVistraMed, NexTel has built a comprehensive healthcare infrastructure. Serving a rapidly expanding nationwide network of over 1,850 online and brick-and-mortar clinics, NexTel uniquely bridges the gap between complex biotechnology innovation and direct clinical application, accelerating its commercial product pipeline while driving long-term shareholder value.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve substantial risks and uncertainties, including completion of clinical testing, regulatory approvals, operational execution, and market acceptance of new products. Actual results could differ materially from those projected or implied in the forward-looking statements.

Contact:

NexTel Medical Corp.

info@nextelmedical.com

www.nextelmedical.com
X: @NexTelMedical

https://finance.yahoo.com/healthcare/articles/nextel-medical-outlines-revenue-model-110000058.html via
@Yahoo @NexTelMedical
#Medical #Sales #Revenue #Growth

$MAJI News: NexTel Medical Corp. Announces Groundbreaking, First-of-Its-Kind Exosome Characterization Study with Penn State University
June 09, 2026 07:00 ET | Source: Exousia Pro, Inc.

Led by Scientific Advisory Board Members Dr. John Bitzer and Dr. Marvin Hausman, the Study Utilizes Advanced Mass Spectrometry to Identify the Precise Bioactive Healing Compounds Within Proprietary Mushroom Exosomes, Driving New Patent Filings and Product Pipelines.

ORLANDO, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems and integrated telehealth solutions, today announced a historic, first-of-its-kind analytical study in collaboration with Pennsylvania State University and esteemed Scientific Advisory Board (SAB) member, Dr. John Bitzer.

The pioneering study utilizes state-of-the-art mass spectrometry to map and isolate the exact bioactive compounds responsible for the therapeutic and healing properties within NexTel's proprietary mushroom-derived exosomes. The research specifically targets and measures critical therapeutic compounds, including Beta-glucans, Polyphenols, and Terpenoids, among others. According to Dr. Marvin Hausman, Chairman of NexTel's Scientific Advisory Board, NexTel is believed to be the first company in the world to conduct this level of sophisticated molecular analysis on mushroom exosomes.

Mass spectrometry is a high-tech lab technique that allows scientists to take a tiny sample of a substance and instantly determine three things: exactly what it is, how much of it there is, and how its individual pieces are put together.

The profound commercial implications of these preliminary findings have already initiated the drafting of new intellectual property and patent filings. Full comprehensive results from the Penn State study are anticipated by the end of June 2026. Fully decoding the molecular blueprint of these exosomes will accelerate NexTel's product pipeline, fueling highly targeted formulations for the company's rapidly expanding telehealth platform, and potentially opening massive distribution channels in the high-growth functional cosmetic and skincare space.

Executive Commentary

"We are incredibly fortunate to have assembled a world-class Scientific Advisory Board with such deep, specialized expertise in mycology and clinical research," said Matt Dwyer, President and CEO of NexTel Medical Corp. "The ability to execute this landmark study at Penn State alongside Dr. Bitzer was made possible through the strategic vision of our SAB Chairman, Dr. Hausman. Dr. Hausman has built an advisory council that unlocks proprietary insights completely unknown to the rest of the industry. Unlocking the true 'healing code' of these exosomes gives us an extraordinary competitive advantage, translating directly into valuable new patents, disruptive product lines, and advanced future clinical testing."

Our Chairman of the Scientific Advisory Board Stated

"This study represents a paradigm shift in how we understand natural cellular communication using plant-based nutrients. Mass spectrometry (MS) is an analytical tool used to measure the mass-to-charge ratio of molecules and accurately identify the compounds in the exosomes produced by our technology. The mushroom is a key food dating back to early humans and contains key bioactive compounds that play a role in physiologic processes such as inflammation, memory, and anti-aging," added Dr. Marvin S. Hausman, MD, Chairman of the Scientific Advisory Board.

About NexTel Medical Corp.

NexTel Medical Corp. is a pioneering biotechnology company at the intersection of clinical innovation and patient access. The company specializes in developing proprietary, next-generation exosome-based delivery systems designed to maximize the bioavailability and therapeutic efficacy of bioactive compounds. Through its integrated telehealth division, NexTel is dedicated to streamlining the commercialization pipeline, delivering cutting-edge, clinically backed wellness and longevity therapies directly to patients.

Forward-Looking Statements: This press release contains forward-looking statements regarding the development and commercialization of NexTel Medical Corp's products. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. NexTel Medical Corp's forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of NexTel Medical Corp., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

NexTel Medical Corp.

info@nextelmedical.com
www.nextelmedical.com
X: @NexTelMedical

$MAJI NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization
Acquisitions bring immediate $135,000 in monthly recurring revenue prior to near-term scaling initiatives; Transaction structured as non-dilutive to $MAJI shareholders.

ORLANDO, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced a major milestone in its corporate growth strategy with the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms: JumpstartRx and NueVistraMed.

The strategic acquisitions immediately inject $135,000 per month in baseline revenue into NexTel’s portfolio, with substantial near-term revenue expansion anticipated as several high-margin clinical initiatives come online later this year.

Transaction Details and Financial Structure Under the terms of the definitive agreements, NexTel will acquire both entities for a total consideration of $8 million, consisting of $2 million in cash and $6 million in preferred stock. The transaction is structured to align performance with long-term shareholder value, featuring a $1 million performance-based bonus upon the achievement of specific revenue projections, alongside structured claw-back provisions if designated operational benchmarks are not achieved. [Supplemental Information filed June 2, 2026].

Significantly, NexTel intends to utilize proceeds from its LMMY shares to fund the transaction. Consequently, there will be no share dilution to existing $MAJI stockholders. The final closing of the transaction is anticipated to take place within 60 to 75 days, subject to the delivery of audited financial statements for both JumpstartRx and NueVistraMed.

Strategic Synergy & Revenue Growth Drivers The current combined baseline revenue of $135,000 per month represents highly scalable future revenue streams poised for immediate integration, including recurring high-margin injectables and nationwide testosterone prescriptions across all associated clinics, which generate a baseline of an anticipated $4.00 per script.

Furthermore, this transaction serves as a massive operational launchpad for NexTel's upcoming proprietary product line, Maxasome™. The combined platforms bring an established distribution network consisting of more than 1,500 online clinics and 350 brick-and-mortar medical facilities, providing an instant, highly receptive commercial channel for NexTel's patent-protected and patent-pending exosome technologies.

Executive Commentary

"We are thrilled to officially welcome JumpstartRx, NueVistraMed, and their visionary founder, Casey Barksdale, to the NexTel family," said Matt Dwyer, President of NexTel Medical Corp. "Casey and his team will be instrumental drivers of our expansion into the multi-billion-dollar wellness industry. Crucially, their existing infrastructure will directly propel the commercial rollout of Maxasome™. Casey has already provided invaluable insights into novel clinical applications for exosomes. Together, we have formulated a product line that we believe vastly outperforms current market alternatives, and his team is uniquely positioned to maximize its commercial adoption."

Casey Barksdale, Founder of JumpstartRx and NueVistraMed, added:

"As an organization deeply committed to clinical excellence, patient outcomes, and medicine affordability, this merger represents an extraordinary milestone. Joining forces with NexTel allows us to execute a highly consolidated, aggressive effort to bring next-generation diagnostic tests and therapies to market through diversified distribution channels. Our unified goal is clear: empower providers to detect health issues earlier through advanced screening, and leverage our robust pharmaceutical partnerships to enhance patient quality of life and longevity."

Portfolio Company Overviews

About JumpstartRx (www.Jumpstartrx.com) JumpstartRx is an innovative, direct-to-consumer telehealth platform tailored to integrate seamlessly with large organizations, enterprise employers, and affinity groups. The platform provides members with streamlined, cost-effective access to essential wellness medications, optimizing workforce health while directly enhancing the corporate bottom line. JumpstartRx differentiates itself by delivering cutting-edge medicine delivery systems and sustainable pharmaceutical discounts for everyday families.

About NueVistraMed (www.NuevistraMed.com) NueVistraMed is a comprehensive, institutional ecosystem for medical clinics, empowering healthcare providers with immense collective buying power. The company provides over 1,850 combined digital and physical clinics with priority access to leading wellness pharmaceuticals, medical supplies, proprietary credit card processing, and integrated employee benefits. Committed to improving patient outcomes, keeping pace with medical technology, and enhancing clinical profitability, NueVistraMed provides partners with patent-pending delivery systems designed for rapid absorption and superior bioavailability. The company also maintains a strategic manufacturing agreement with a prominent 503B compounding facility to produce highly affordable, accessible testosterone therapies.

About NexTel Medical Corp.

NexTel Medical Corp. (OTCPK: MAJI) is a pioneering biotechnology leader at the forefront of exosome research, clinical diagnostics, and wellness accessibility. The Company specializes in developing proprietary, next-generation, exosome-based delivery systems and non-invasive screening tools designed to revolutionize both therapeutic and diagnostic modalities. By leveraging proprietary filtration and stabilization techniques, NexTel provides high-purity, additive-free solutions for the future of personalized medicine.

Following its strategic acquisitions of JumpstartRx and NueVistraMed, NexTel’s rapidly expanding telehealth and clinical solutions division bridges the gap between complex biotechnology innovation and direct clinical application. Serving a network of over 1,850 online and brick-and-mortar clinics nationwide, NexTel is uniquely positioned to accelerate the launch of its commercial product pipeline, including its flagship Maxasome™ line, while driving immediate revenue growth and long-term shareholder value.

Forward-Looking Statements: This press release contains forward-looking statements regarding the development and commercialization of NexTel Medical Corp’s products. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. NexTel Medical Corp's forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of NexTel Medical Corp., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

NexTel Medical Corp.

info@nextelmedical.com
www.nextelmedical.com
X: @NexTelMedical

https://www.globenewswire.com/newsroom/ti?nf=OTczMDU3OCM3NjMyOTQyIzUwMDE1ODM1Mg==
https://ml.globenewswire.com/media/MDJkMDRkNDctNDIxZi00YjNiLTk3YWMtMDc2ODBlZjNmODE0LTUwMDE1ODM1Mi0yMDI2LTA2LTAyLWVu/tiny/Exousia-Pro-Inc-.png

Source: Exousia Pro, Inc.

Not anymore lol 

$MAJI - run coming…nice update from the company!!

Why did the outstanding shares go up 5 million

Exciting news for $MAJI: When our site is live! Anyone interested in joining our groundbreaking cancer screening study can now sign up directly online. Once enrolled, you’ll receive a comprehensive at-home collection kit with clear instructions for a seamless return. Your results will be delivered securely via email, and all data is strictly managed under HIPAA guidelines to ensure your privacy. Join us in advancing early detection!..more to come.
Exciting news for $MAJI: When our site is live! Anyone interested in joining our groundbreaking cancer screening study can now sign up directly online. Once enrolled, you’ll receive a comprehensive at-home collection kit with clear instructions for a seamless return. Your results… pic.twitter.com/on7QdicFeA— NextTel Medical Corp (@NexTelMedical) March 26, 2026

$MAJI — the telehealth company with which we are finalizing a definitive agreement — is currently renegotiating terms with 1,900 clinics to expand its role as sole distributor beyond testosterone. The existing testosterone program alone generates approximately $4 per script across an estimated 2,000 daily prescriptions, highlighting meaningful revenue potential with significant upside as the partnership broadens.

The share price won’t jump up instantly after the share reduction will it?
Anyone have experience with this scenario?

Big news for $MAJI shareholders: We are nearing the execution of our first Definitive Agreement, covering two of our Telehealth acquisitions! To mark the occasion, we’re hosting a special session with @buffalofireside featuring the founder from these companies. This is a rare opportunity to hear directly from the visionary behind these two acquisitions, as well as about our integration strategy and the future of our telehealth ecosystem. Stay tuned for the official announcement—you won't want to miss this DD!...more to come.
Big news for $MAJI shareholders: We are nearing the execution of our first Definitive Agreement, covering two of our Telehealth acquisitions! To mark the occasion, we’re hosting a special session with @buffalofireside featuring the founder from these companies. This is a rare… pic.twitter.com/gZHBs6Ik0P— NextTel Medical Corp (@NexTelMedical) March 23, 2026

$MAJI - shares corporate update. pic.twitter.com/AxtRBNRLQm— NextTel Medical Corp (@NexTelMedical) March 19, 2026

$MAJI is officially NexTel Medical Corp!
We are thrilled to announce our formal name change, reflecting a strategic evolution into the broader wellness and biotechnology space. While our identity is growing, we remain deeply rooted in our cutting-edge exosome technology, continuing the vital work on our cancer screening tests and premium wellness products.
Integrating the telehealth sector presents a transformative opportunity to scale our operations and build a dedicated, in-house consumer base for our exosome-driven innovations. This is just the beginning. Our application to FINRA will be submitted shortly.—more major updates are on the horizon!
$MAJI is officially NexTel Medical Corp!
We are thrilled to announce our formal name change, reflecting a strategic evolution into the broader wellness and biotechnology space. While our identity is growing, we remain deeply rooted in our cutting-edge exosome technology,… pic.twitter.com/QJEzLOr3XT— NextTel Medical Corp (@NexTelMedical) March 19, 2026

$MAJI is officially NexTel Medical Corp!We are thrilled to announce our formal name change, reflecting a strategic evolution into the broader wellness and biotechnology space. While our identity is growing, we remain deeply rooted in our cutting-edge exosome technology, continuing the vital work on our cancer screening tests and premium wellness products.
Integrating the telehealth sector presents a transformative opportunity to scale our operations and build a dedicated, in-house consumer base for our exosome-driven innovations. This is just the beginning. Our application to FINRA will be submitted shortly.—more major updates are on the horizon!

$MAJI The new site starting to come together and showing some insight if you dig around.. 
CANCER TESTING COMING! 👇👇👇👇👇👇
nextelmedical.com/cancertesting

$MAJI is shifting into high gear! With 100% of our time and energy now dedicated to scaling the company, our roadmap for the rest of March is packed with transformative milestones.
$MAJI is shifting into high gear! With 100% of our time and energy now dedicated to scaling the company, our roadmap for the rest of March is packed with transformative milestones. pic.twitter.com/QNl7VPp3T5— NextTel Medical Corp (@NexTelMedical) March 17, 2026

https://investorshub.advfn.com/stock-market/USOTC/marijuana-pk-MAJI/stock-news/98061370/exousia-pro-inc-announces-favorable-litigation-s

Next stop: March 13th. We head into mediation with the defendants from a position of strength. We are seeking the full cancellation of even more restricted shares to protect the float. Stay tuned—I'll be updating you live from the room. $MAJI

Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions

https://www.globenewswire.com/news-release/2026/03/05/3250550/0/en/Exousia-Pro-Inc-Announces-Strategic-Elimination-of-Future-Dilutive-Issuance-of-47-Million-Shares-Progresses-Toward-Definitive-Agreements-for-Telehealth-Acquisitions.html

$MAJI is pleased to announce that we have formally submitted documentation to change the Company’s name to Nextel Medical Corp, marking an important step in our strategic evolution. The filing process is expected to take approximately 3–5 business days. Shareholders may monitor the status of the name change at Sunbiz.org. Additional updates will be provided as they become available.

Back on board here.

$MAJI is thrilled to announce that we have officially executed the documentation to cancel the shares.
This cancellation effectively increases the relative ownership stake of our steadfast loyal shareholders and optimizes our capital structure. This is a major step in our commitment to enhancing long-term shareholder value. Final confirmation will follow as we receive the executed stock power...more to come!!!
$MAJI is thrilled to announce that we have officially executed the documentation to cancel the shares.

This cancellation effectively increases the relative ownership stake of our steadfast loyal shareholders and optimizes our capital structure. This is a major step in our… pic.twitter.com/m4K7EuI0Kh— NextTel Medical Corp (@NexTelMedical) February 27, 2026

$MAJI Shareholders | we’ve got an exciting lineup of updates queued up as we accelerate into our next major growth phase! The whole team is excited and we’re beyond thrilled about what’s ahead. Thank you for growing with us — let’s build something incredible together! pic.twitter.com/yisUdyRrCQ— NextTel Medical Corp (@NexTelMedical) February 26, 2026

$MAJI Shareholders | we’ve got an exciting lineup of updates queued up as we accelerate into our next major growth phase! The whole team is excited and we’re beyond thrilled about what’s ahead. Thank you for growing with us — let’s build something incredible together!

sweet! finally starting to move

$MAJI is nearing the finalization of a strategic agreement expected to generate more than $100 million in annual revenues for its telehealth division. We look forward to executing the agreement in the coming weeks and sharing further updates as progress continues.
$MAJI is nearing the finalization of a strategic agreement expected to generate more than $100 million in annual revenues for its telehealth division. We look forward to executing the agreement in the coming weeks and sharing further updates as progress continues.— NextTel Medical Corp (@NexTelMedical) February 25, 2026

$MAJI is nearing the finalization of a strategic agreement expected to generate more than $100 million in annual revenues for its telehealth division. We look forward to executing the agreement in the coming weeks and sharing further updates as progress continues.

Yes, these are indeed good tidings. It made absolutely no sense to me that the CEO named this company after a federally prohibited Schedule One drug. I think that was terribly shortsighted to put it nicely. And while the name change news is certainly welcome, the process can take several weeks--at a minimum--or even longer than a year. As always, we'll see...

Exciting news! $MAJI will officially become NexTel Medical Corp.
Our new identity reflects our renewed commitment to the future of healthcare as we enter the Telehealth space and launch our breakthrough patented Cancer Screening kit. We are well underway in building a brand that matches the scale of our medical innovations. The future of remote diagnostics starts now!
Exciting news! $MAJI will officially become NexTel Medical Corp.

Our new identity reflects our renewed commitment to the future of healthcare as we enter the Telehealth space and launch our breakthrough patented Cancer Screening kit. We are well underway in building a brand that…— NextTel Medical Corp (@NexTelMedical) February 24, 2026

yes saw that hopefully we get traction now

yes saw that hopefully we get traction now

$MAJI Corporate Update: We are pleased to announce that the formal documentation for our planned share cancellation has been delivered for final execution.
We anticipate confirming the completion of this share cancellation later this week. This move reflects our ongoing commitment to optimizing our capital structure and enhancing long-term shareholder value. Stay tuned for further updates!
$MAJI Corporate Update: We are pleased to announce that the formal documentation for our planned share cancellation has been delivered for final execution.

We anticipate confirming the completion of this share cancellation later this week. This move reflects our ongoing…— NextTel Medical Corp (@NexTelMedical) February 23, 2026

its bizarre maybe peeps not believing til it happens

With that in mind, can you explain why the PPS keeps dropping instead of slowly (or quickly) ascending? Just curious...

>25mill shares of a 44mill OS per the company!!
$MAJI
Even bigger than we thought!!
>25mill shares of a 44mill OS per the company!! pic.twitter.com/IeC2LkSQkd— Investing 4 Life (@StockBullPicks) February 18, 2026

took some share reductions are always nice $MAJI - Will announce a Significant share cancellation in the coming days! Stay Tuned!!!! pic.twitter.com/NsMty6yMja— NextTel Medical Corp (@NexTelMedical) February 18, 2026

Big news for the future of preventative health! $MAJI is launching an upgraded website in the coming weeks.
As part of our expanded clinical study, we are inviting participants to sign up for our new Patented Cancer Screening Kit—completely free of charge. Your privacy is our priority; all data is strictly protected under HIPAA compliance. Join us in pioneering accessible early detection.
Big news for the future of preventative health! $MAJI is launching an upgraded website in the coming weeks.

As part of our expanded clinical study, we are inviting participants to sign up for our new Patented Cancer Screening Kit—completely free of charge. Your privacy is our… pic.twitter.com/CBRLC857qw— NextTel Medical Corp (@NexTelMedical) February 12, 2026

Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition

https://www.globenewswire.com/news-release/2026/02/10/3235529/0/en/Exousia-Pro-Inc-Accelerates-Strategic-Expansion-with-Third-Telehealth-Acquisition-Strengthens-Pathway-to-Low-Cost-Customer-Acquisition.html

Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition

Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition https://t.co/QRZSwabKe9— NextTel Medical Corp (@NexTelMedical) February 10, 2026

Mediation scheduled for March 13.

It means the US Mail has gone to hell? Everything has. The new Motto is:

Our Service is fast no matter how long it takes

Ask Toni:

Referred to Collections ExousiaPro Inc referred to Collections Agency through automated process
Latest court entry. What does it mean?

Yes, I believe an out of court settlement is what will happen.

I saw that this weekend. Does that mean they will try to come to an agreement without the court. I don’t know how these things work.

COME NOW, the Defendants, by and through their undersigned counsel, and hereby give Notice to
this Court that the parties to this action have agreed to use Richard Marchewka, Esquire as their Mediator.

https://matrix.leeclerk.org/Case/DocViewer?pdfName=D113BA6F-FFD2-422D-BD83-FC337567CC8A.pdf

The current CEO brought in new cancer cure tech to dead scam, and Maji now already has US FDA orphan drug designated tech for Glioblastoma brain cancer, using a natural compound and blood brain crossing Exozome tech, to kill brain cancer stem cells that Maji has the right stuff to eliminate Glioblastoma brain cancer completely. It also now owns over 51% of LMMY, that is Nasdaq Bound.

And the Ex-Con, US DEA convicted criminal that illegally printed shares that a federal court is already in the process of nailing him for printing and selling, and expecting to force him to buy back and return, is well underway.

Facts Matter.

Smart people buy the Dips and know what they own and know wtf is going on, like me.

Fell free to act dumb and keep selling me shares at 80% the High that the current CEO got us to before the Ex CEO F**ked us all.

Or did he just fill my wallet with way more shares than I dreamed I could score at 80% off?

Stock pps was higher with former CEO

Motion denied . Good news for us! At least I think so.

Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization

https://www.accessnewswire.com/newsroom/en/exousia-pro-inc.-announces-executed-loi-for-strategic-acquisition-of-high-revenue-telehealth-platf-1116791

$LMMY – Exousia Bio is seeking ways to expand upon its Orphan Drug Designation for Malignant glioma. Our science and medical team are researching rare diseases with unmet medical needs. We plan to file for multiple Orphan Drug Designations under our existing approved Orphan Drug Designation, for these rare diseases, further enhancing the value of our technology.
https://t.co/byeneKUzOn— @ExousiaBio (@ExousiaBio) December 10, 2025

LessIsMoron..... LOL,

Got it...Moron!!!